Historical valuation data is not available at this time.
Shandong Xinhua Pharmaceutical Company Limited is a major Chinese pharmaceutical manufacturer headquartered in Zibo, Shandong Province. The company operates primarily in the production and sale of chemical APIs (Active Pharmaceutical Ingredients), pharmaceutical preparations, and healthcare products. It holds a significant position in the domestic market, particularly in antipyretic and analgesic drugs, with its flagship product, antipyrine and analgesics such as aspirin and paracetamol (acetaminophen), being core revenue drivers. Xinhua Pharmaceutical is also involved in the manufacturing of caffeine and other chemical intermediates, supplying both domestic and international markets. The company benefits from integrated production capabilities, economies of scale, and a well-established distribution network within China, though it faces intense competition from both state-owned and private pharmaceutical enterprises.
Engages in R&D for process optimization and new drug formulations; holds patents related to manufacturing processes for chemicals like caffeine and analgesics; however, innovation focus is more on cost efficiency rather than breakthrough pharmaceuticals
Shandong Xinhua Pharmaceutical represents a established player in China's pharmaceutical chemical sector with strengths in scale and cost-competitive production. However, it operates in a highly regulated and competitive environment, with margins susceptible to raw material costs and regulatory changes. Investment appeal hinges on execution of efficiency upgrades, export expansion, and ability to navigate environmental regulations. Risks include regulatory scrutiny and competitive pressures, necessitating careful review of recent financials and industry trends.